FDA Approves Avastin Biosimilar Agent, Jobevne

Biocon Biologics signs US settlement with Regeneron to Launch Yesafili Biosimilar by 2026 - Express Pharma

Biocon Biologics (BBL), a subsidiary of Biocon, has entered into a settlement and licence agreement with Regeneron Pharmaceuticals, enabling the future commercialisation of its interchangeable aflibercept biosimilar, Yesafili (aflibercept-jbvf), in the United States. The agreement settles ongoing litigation related to US Patent No. 11084865 (‘865 patent), which was pending before the United States Court of Appeals for the Federal Circuit and the…

U.S. FDA grants interchangeable designation to YUFLYMA® (adalimumab-aaty), Celltrion's biosimilar to Humira® (adalimumab)

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar, that is now interchangeable [1] Interchangeable designation of YUFLYMA® is supported by positive data from the Phase III interchangeability study in patients with moderate-to-severe plaque psoriasis INCHEON, South Korea, April 14, 2025 /PRNewswire/ — Celltrion, Inc. today announced that the U.S. Food and Drug Administrat…

Biocon Biologics Announces US FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio

Biocon Biologics announced that the US FDA has approved Jobevne, a biosimilar Bevacizumab for intravenous use. JOBEVNE is a VEGF inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis. [Biocon Biologics] Press Release

Celltrion gets interchangeability approval for biosimilar of...

Last Updated on April 14, 2025 by Team THIP Seoul, April 14 (IANS) Celltrion, a major South Korean biopharmaceutical firm, on Monday said it has obtained an interchangeability approval for its biosimilar drug for autoimmune disease treatment in the United States. The US Food and Drug Administration (FDA) designated Celltrion’s biosimilar Yuflyma as interchangeable medicine […] The post Celltrion gets interchangeability approval for biosimilar of…

FDA Approves Avastin Biosimilar Agent, Jobevne

The agent is approved for use in various combinations across numerous cancer types. Medscape Medical News